Her main research concerns Amyloidosis, Internal medicine, AL amyloidosis, Immunology and Pathology. The various areas that Helen J. Lachmann examines in her Amyloidosis study include Hazard ratio, Cardiology and Amyloid. Her Internal medicine study incorporates themes from Gastroenterology and Surgery.
Helen J. Lachmann focuses mostly in the field of AL amyloidosis, narrowing it down to topics relating to Chemotherapy and, in certain cases, Thalidomide, Discontinuation and Proteasome inhibitor. Her studies in Immunology integrate themes in fields like Canakinumab and AA amyloidosis. Her work deals with themes such as Genetic testing, Clone and Multiple myeloma, which intersect with Pathology.
Helen J. Lachmann spends much of her time researching Internal medicine, Amyloidosis, AL amyloidosis, Pathology and Immunology. Her Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Surgery and Cardiology. Her research investigates the connection with Amyloidosis and areas like Transthyretin which intersect with concerns in Cardiomyopathy.
Her work carried out in the field of AL amyloidosis brings together such families of science as Melphalan, Thalidomide, Chemotherapy and Multiple myeloma. Her Immunology study which covers Familial Mediterranean fever that intersects with MEFV. Her AA amyloidosis research is multidisciplinary, relying on both Complication and Serum Amyloid A Protein.
Her main research concerns Internal medicine, Amyloidosis, AL amyloidosis, Gastroenterology and Disease. Her research in the fields of Bortezomib, AA amyloidosis and Retrospective cohort study overlaps with other disciplines such as In patient. Amyloidosis is the subject of her research, which falls under Pathology.
Her research integrates issues of Lenalidomide, Multiple myeloma, Chemotherapy and Transplantation in her study of AL amyloidosis. Her Gastroenterology study combines topics in areas such as Confidence interval, Hazard ratio, Renal function, Very Good Partial Response and Natriuretic peptide. The concepts of her Disease study are interwoven with issues in Pediatrics, Immunology, MEFV and Intensive care medicine.
Her primary areas of study are Amyloidosis, Internal medicine, Gastroenterology, Immunology and AL amyloidosis. Her Amyloidosis study is concerned with Pathology in general. Her study in Cardiac amyloidosis, Adverse effect, Familial Mediterranean fever, Retrospective cohort study and Serum amyloid A are all subfields of Internal medicine.
Her Gastroenterology research focuses on Hazard ratio and how it relates to Treatment options and Autologous stem-cell transplantation. Her Immunology study combines topics from a wide range of disciplines, such as Canakinumab, Anakinra and Downregulation and upregulation. Her biological study spans a wide range of topics, including Observational study, Response Duration, Chemotherapy, Survival rate and Bortezomib.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Julian D. Gillmore;Mathew S. Maurer;Rodney H. Falk;Giampaolo Merlini.
Natural history and outcome in systemic AA amyloidosis.
Helen J Lachmann;Hugh J B Goodman;Janet A Gilbertson;J Ruth Gallimore.
The New England Journal of Medicine (2007)
Use of canakinumab in the cryopyrin-associated periodic syndrome.
Helen J Lachmann;Isabelle Kone-Paut;Jasmin B Kuemmerle-Deschner;Kieron S Leslie.
The New England Journal of Medicine (2009)
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.
Helen J Lachmann;David R Booth;Susanne E Booth;Alison Bybee.
The New England Journal of Medicine (2002)
Spectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Philip N. Hawkins;Helen J. Lachmann;Ebun Aganna;Michael F. McDermott.
Arthritis & Rheumatism (2004)
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
M. B. Pepys;J. Herbert;W. L. Hutchinson;G. A. Tennent.
Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.
Philip N. Hawkins;Helen J. Lachmann;Michael F. McDermott.
The New England Journal of Medicine (2003)
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
Helen J. Lachmann;Ruth Gallimore;Julian D. Gillmore;Hugh D. Carr-Smith.
British Journal of Haematology (2003)
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis.
Ebun Aganna;Fabio Martinon;Philip N. Hawkins;John B. Ross.
Arthritis & Rheumatism (2002)
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
Marianna Fontana;Silvia Pica;Patricia Reant;Amna Abdel-Gadir.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: